Cost-effectiveness of imatinib versus interferon-alpha in the treatment of patients newly diagnosed with chronic myeloid leukemia, under the Brazilian public healthcare system perspective.

Mataveli, FabioCalabro, AlessandraMendes, WellingtonVianna, DenizarDorlhiac-Llacer, PedroBigni, RicardoHungria, Vania2014-05-202014-05-202006-11-16Blood. Washington: Amer Soc Hematology, v. 108, n. 11, p. 946A-946A, 2006.0006-4971http://hdl.handle.net/11449/36287946A-946AengCost-effectiveness of imatinib versus interferon-alpha in the treatment of patients newly diagnosed with chronic myeloid leukemia, under the Brazilian public healthcare system perspective.ResumoWOS:000242440004362Acesso restrito